TRB Chemedica (UK) Limited 31/12/2025 iXBRL

Company registration number: 04327806

TRB Chemedica (UK) Limited

Filleted financial statements

31 December 2025

TRB Chemedica (UK) Limited

Contents

Directors and other information

Directors responsibilities statement

Statement of financial position

Notes to the financial statements

TRB Chemedica (UK) Limited

Directors and other information


Directors	Mr Desmond Flanagan	(Resigned 1 January 2026)
	Ms Janet Lea
	Mr Isaac Abad
	Mr Alessandro Di Napoli
	Mr Ben Taylor Dingwall	(Appointed 1 July 2025)


Secretary	Mr Desmond Flanagan	(Resigned 1 January 2026)


Company number	04327806


Registered office	9 Evolution
	Hooters Hall Road
	Lymedale Business Park
	Newcastle under Lyme
	ST5 9QF


Business address	9 Evolution
	Hooters Hall Road
	Lymedale Business Park
	Newcastle under Lyme
	ST5 9QF


Auditor	Jacksons
	Chartered Accountants
	Deansfield House
	98 Lancaster Road
	Newcastle under Lyme
	Staffordshire
	ST5 1DS

TRB Chemedica (UK) Limited

Directors responsibilities statement

Year ended 31 December 2025

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;

- make judgments and accounting estimates that are reasonable and prudent; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

TRB Chemedica (UK) Limited

Statement of financial position

31 December 2025

		2025		2024
	Note	£	£	£	£

Fixed assets
Intangible assets	5	2,400		5,280
Tangible assets	6	477,172		466,371
		_______		_______
			479,572		471,651

Current assets
Stocks		550,016		577,019
Debtors	7	460,646		325,003
Cash at bank and in hand		150,471		145,457
		_______		_______
		1,161,133		1,047,479
Creditors: amounts falling due
within one year	8	( 520,959)		( 368,564)
		_______		_______
Net current assets			640,174		678,915
			_______		_______
Total assets less current liabilities			1,119,746		1,150,566

Creditors: amounts falling due
after more than one year	9		-		( 48,389)

Provisions for liabilities			( 16,021)		( 13,488)

			_______		_______
Net assets			1,103,725		1,088,689
			_______		_______

Capital and reserves
Called up share capital			300,000		300,000
Profit and loss account			803,725		788,689
			_______		_______
Shareholders funds			1,103,725		1,088,689
			_______		_______

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 31 March 2026 , and are signed on behalf of the board by:

Mr Ben Taylor Dingwall

Director

Company registration number: 04327806

TRB Chemedica (UK) Limited

Notes to the financial statements

Year ended 31 December 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 9 Evolution, Hooters Hall Road, Lymedale Business Park, Newcastle under Lyme, ST5 9QF.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Operating leases

Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.

Intangible assets

Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at a revalued amount, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:


Intangible assets	-	25% Straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:


Long leasehold property	-	1% Straight line
Fittings fixtures and equipment	-	25% Straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Provisions

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.Debt instruments are subsequently measured at amortised cost.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. The plan is in respect of all employees and directors and the plan and its assets are held by independent managers.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 14 (2024: 12 ).

5. Intangible assets

	Other intangible assets	Total
	£	£
Cost
At 1 January 2025 and 31 December 2025	11,520	11,520
	_______	_______
Amortisation
At 1 January 2025	6,240	6,240
Charge for the year	2,880	2,880
	_______	_______
At 31 December 2025	9,120	9,120
	_______	_______
Carrying amount
At 31 December 2025	2,400	2,400
	_______	_______
At 31 December 2024	5,280	5,280
	_______	_______

6. Tangible assets

	Long leasehold property	Fixtures, fittings and equipment	Total
	£	£	£
Cost
At 1 January 2025	461,120	181,815	642,935
Additions	-	42,596	42,596
Disposals	-	( 4,861)	( 4,861)
	_______	_______	_______
At 31 December 2025	461,120	219,550	680,670
	_______	_______	_______
Depreciation
At 1 January 2025	43,421	133,143	176,564
Charge for the year	4,611	26,163	30,774
Disposals	-	( 3,840)	( 3,840)
	_______	_______	_______
At 31 December 2025	48,032	155,466	203,498
	_______	_______	_______
Carrying amount
At 31 December 2025	413,088	64,084	477,172
	_______	_______	_______
At 31 December 2024	417,699	48,672	466,371
	_______	_______	_______

7. Debtors

	2025	2024
	£	£
Trade debtors	378,469	272,143
Other debtors	82,177	52,860
	_______	_______
	460,646	325,003
	_______	_______

8. Creditors: amounts falling due within one year

	2025	2024
	£	£
Bank loan	4,406	10,399
Trade creditors	85,231	101,842
Amounts owed to group undertakings and undertakings in which the company has a participating interest	191,417	44,000
Corporation tax	12,461	23,743
Social security and other taxes	76,004	68,338
Other creditors	151,440	120,242
	_______	_______
	520,959	368,564
	_______	_______

9. Creditors: amounts falling due after more than one year

	2025	2024
	£	£
Bank loan	-	4,389
Amounts owed to group undertakings and undertakings in which the company has a participating interest	-	44,000
	_______	_______
	-	48,389
	_______	_______

10. Operating leases

The company as lessee

The total future minimum lease payments under non-cancellable operating leases are as follows:


	£	£

Not later than 1 year	12,842	12,842
Later than 1 year and not later than 5 years	22,148	34,690
Later than 5 years	292,800	293,100
	_______	_______
	327,790	340,632
	_______	_______

Included within the operating lease payments above is a ground rent commitment on the long leasehold property of 981 years at £300 per annum (2024: 982 years at £300 per annum).

11. Summary audit opinion

The auditor's report dated 31 March 2026 was unqualified.

The senior statutory auditor was David McDonald for and on behalf of Jacksons

12. Directors advances, credits and guarantees

	During the year the directors entered into the following advances and credits with the company:

2025
		Balance brought forward	Advances /(credits) to the directors	Balance o/standing
		£	£	£
	Mr Desmond Flanagan	564	( 564)	-
	Ms Janet Lea	986	14	1,000
		_______	_______	_______
		1,550	( 550)	1,000
		_______	_______	_______

2024
		Balance brought forward	Advances /(credits) to the directors	Balance o/standing
		£	£	£
	Mr Desmond Flanagan	( 2,073)	2,637	564
	Ms Janet Lea	1,000	( 14)	986
		_______	_______	_______
		( 1,073)	2,623	1,550
		_______	_______	_______

13. Related party transactions

Mr Ben Taylor Dingwall , Mr Desmond Flanagan , Ms Janet Lea , Mr Isaac Abad and Mr Alessandro Di Napoli are related parties by virtue of their directorships of the company.Included within debtors is an interest free loan from the company to the directors totalling £1,000 (2024: £1,550) as disclosed in the Directors' advances, credits and guarantees note to the financial statements. The purpose of the loan is to act as a company expenses float. During the year, Mr Desmond Flanagan repaid his £564 expenses float in full.During the year, Mr Ben Taylor Dingwall has provided the company with an interest free loan and the balance owed by the company at the year end was £1,597 (2024: £1,321 owed to the company).TMB Holding S.A. owns 100% of the issued share capital of TRB Chemedica (UK) Limited .TRB Chemedica International S.A. is a wholly owned subsidiary of TMB Holding S.A.During the year, the company purchased goods totalling £675,772 (2024: £873,979) from TRB Chemedica International S.A. and at the year end the company owed £147,417 to TRB Chemedica International S.A. (2024: £58,402). During the year, TRB Middle East FZE recharged expenses to the company totalling £nil (2024: £2,436).During the year, the company recharged expenses to TRB Chemedica (Thailand) Ltd totalling £21,000 (2024: £36,000).During the year, the company recharged expenses to TRB Chemedica Malaysia Sdn Bhd totalling £nil (2024: £9,467).During the year, Alex Flanagan Management Ltd, a company in which Mr Desmond Flanagan is a director, provided clinical consultancy and support services to the company totalling £25,300 (2024: £nil) and at the year end the company owed £5,000 (2024: £nil).TMB Holding S.A. has provided the company with an unsecured loan in the sum of £440,000. The loan is repayable annually over 10 years and interest is charged at a rate of 4.5% per annum. At the year end, the balance owed to TMB Holding S.A. was £44,000 (2024: £88,000). During the year, the company paid interest to TMB Holding S.A. totalling £3,979 (2024: £4,697).WICK SARL was established and is managed by Mr. Alessandro Di Napoli following a strategic decision by the group to centralise and optimise technical expertise. The objective is to streamline the provision of technical support across the group's subsidiaries, ensuring efficiency and alignment with the specific requirements of its respective market. As a result of the specialised consultancy and technical support services provided to the company in 2025 and totalling £24,037 (2024: £10,426), the company owes £2,616 to WICK SARL (2024: £2,072.)

14. Controlling party

The parent of the smallest group for which consolidated financial statements are drawn up of which the company is a member, is TMB Holding S.A., a company incorporated in Switzerland. The registered office of TMB Holding S.A is Kernserstrasse 31, Postfach 1654, 6061 Sarnen, Switzerland. The financial statements for the group can be located at its registered office.